Literature DB >> 16707749

Volume progression in polycystic kidney disease.

Jared J Grantham1, Vicente E Torres, Arlene B Chapman, Lisa M Guay-Woodford, Kyongtae T Bae, Bernard F King, Louis H Wetzel, Deborah A Baumgarten, Phillip J Kenney, Peter C Harris, Saulo Klahr, William M Bennett, Gladys N Hirschman, Catherine M Meyers, Xiaoling Zhang, Fang Zhu, John P Miller.   

Abstract

BACKGROUND: Autosomal dominant polycystic kidney disease (ADPKD) is characterized by progressive enlargement of cyst-filled kidneys.
METHODS: In a three-year study, we measured the rates of change in total kidney volume, total cyst volume, and iothalamate clearance in patients with ADPKD. Of a total of 241 patients, in 232 patients without azotemia who were 15 to 46 years old at baseline we used magnetic-resonance imaging to correlate the total kidney volume and total cyst volume with iothalamate clearance. Statistical methods included analysis of variance, Pearson correlation, and multivariate regression analysis.
RESULTS: Total kidney volume and total cyst volume increased exponentially, a result consistent with an expansion process dependent on growth. The mean (+/-SD) total kidney volume was 1060+/-642 ml at baseline and increased by a mean of 204+/-246 ml (5.27+/-3.92 percent per year, P<0.001) over a three-year period among 214 patients. Total cyst volume increased by 218+/-263 ml (P<0.001) during the same period among 210 patients. The baseline total kidney volume predicted the subsequent rate of increase in volume, independently of age. A baseline total kidney volume above 1500 ml in 51 patients was associated with a declining glomerular filtration rate (by 4.33+/-8.07 ml per minute per year, P<0.001). Total kidney volume increased more in 135 patients with PKD1 mutations (by 245+/-268 ml) than in 28 patients with PKD2 mutations (by 136+/-100 ml, P=0.03).
CONCLUSIONS: Kidney enlargement resulting from the expansion of cysts in patients with ADPKD is continuous and quantifiable and is associated with the decline of renal function. Higher rates of kidney enlargement are associated with a more rapid decrease in renal function. Copyright 2006 Massachusetts Medical Society.

Entities:  

Mesh:

Year:  2006        PMID: 16707749     DOI: 10.1056/NEJMoa054341

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  302 in total

1.  Scattered Deletion of PKD1 in Kidneys Causes a Cystic Snowball Effect and Recapitulates Polycystic Kidney Disease.

Authors:  Wouter N Leonhard; Malu Zandbergen; Kimberley Veraar; Susan van den Berg; Louise van der Weerd; Martijn Breuning; Emile de Heer; Dorien J M Peters
Journal:  J Am Soc Nephrol       Date:  2014-10-31       Impact factor: 10.121

2.  Hypertension in Autosomal Dominant Polycystic Kidney Disease: A Clinical and Basic Science Perspective.

Authors:  Shobha Ratnam; Surya M Nauli
Journal:  Int J Nephrol Urol       Date:  2010

3.  Blood pressure in early autosomal dominant polycystic kidney disease.

Authors:  Robert W Schrier; Kaleab Z Abebe; Ronald D Perrone; Vicente E Torres; William E Braun; Theodore I Steinman; Franz T Winklhofer; Godela Brosnahan; Peter G Czarnecki; Marie C Hogan; Dana C Miskulin; Frederic F Rahbari-Oskoui; Jared J Grantham; Peter C Harris; Michael F Flessner; Kyongtae T Bae; Charity G Moore; Arlene B Chapman
Journal:  N Engl J Med       Date:  2014-11-15       Impact factor: 91.245

4.  Renal function and healthcare costs in patients with polycystic kidney disease.

Authors:  Krista L Lentine; Huiling Xiao; Gerardo Machnicki; Adrian Gheorghian; Mark A Schnitzler
Journal:  Clin J Am Soc Nephrol       Date:  2010-06-10       Impact factor: 8.237

5.  Therapeutic mTOR inhibition in autosomal dominant polycystic kidney disease: What is the appropriate serum level?

Authors:  G Canaud; B Knebelmann; P C Harris; F Vrtovsnik; J-M Correas; N Pallet; C M Heyer; E Letavernier; F Bienaimé; E Thervet; F Martinez; F Terzi; C Legendre
Journal:  Am J Transplant       Date:  2010-07       Impact factor: 8.086

6.  Evaluating the clinical utility of a molecular genetic test for polycystic kidney disease.

Authors:  Miguel A Garcia-Gonzalez; Jeffrey G Jones; Susan K Allen; Christopher M Palatucci; Sat D Batish; William K Seltzer; Zheng Lan; Erica Allen; Feng Qian; Xose M Lens; York Pei; Gregory G Germino; Terry J Watnick
Journal:  Mol Genet Metab       Date:  2007-06-18       Impact factor: 4.797

7.  Rapid Identification of New Biomarkers for the Classification of GM1 Type 2 Gangliosidosis Using an Unbiased 1H NMR-Linked Metabolomics Strategy.

Authors:  Benita C Percival; Yvonne L Latour; Cynthia J Tifft; Martin Grootveld
Journal:  Cells       Date:  2021-03-05       Impact factor: 6.600

8.  Tubular obstruction leads to progressive proximal tubular injury and atubular glomeruli in polycystic kidney disease.

Authors:  Carolina I Galarreta; Jared J Grantham; Michael S Forbes; Robin L Maser; Darren P Wallace; Robert L Chevalier
Journal:  Am J Pathol       Date:  2014-05-09       Impact factor: 4.307

Review 9.  The importance of total kidney volume in evaluating progression of polycystic kidney disease.

Authors:  Jared J Grantham; Vicente E Torres
Journal:  Nat Rev Nephrol       Date:  2016-10-03       Impact factor: 28.314

Review 10.  Autosomal dominant polycystic kidney disease and transplantation.

Authors:  Mariusz Niemczyk; Stanisław Niemczyk; Leszek Paczek
Journal:  Ann Transplant       Date:  2009 Oct-Dec       Impact factor: 1.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.